NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Arbor Biotechnologies

Arbor Biotechnologies

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://arbor.bio/

Last Round

Series C

Mar 18, 2025

Est. Valuation

$575M

Total Funding Raised

$320.1M

Company Overview

Arbor Biotechnologies is a biotechnology company that develops genomic medicines and gene-editing tools using AI and machine learning to address genetic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Infrastructure

Keywords

gene editingbiotechnologydrug discoveryrare diseasenucleasegenomic medicinetherapeutic candidateAI drug discoverygene therapyprecision medicinebiotech platformorphan drugcomputational biologygenomicsCRISPR

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Arbor Biotechnologies Comps

Public and private peers based on sector, stage, and business model.

Arbor Biotechnologies comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Arbor Biotechnologies Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CMar 18, 2025
Series BNov 9, 2021
Series AAug 2, 2017
Series AJun 1, 2017

Key People

Founding team and executive leadership

Devyn Smith

Chief Executive Officer, CEO

Executive Team

Pam Stetkiewicz

Chief Operating Officer

Executive Team

Arbor Biotechnologies Investors

Notable investors and investment history

Arbor Biotechnologies investors
InvestorRounds
GreatPoint VenturesSeries B
S32Series B
Surveyor CapitalSeries C, Series B
Janus Henderson GroupSeries B
Aberdeen Group plcSeries C
TemasekSeries C, Series B
TCG CrossoverSeries C, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 1, 2026

    Lead program ABO-101 enters clinical trials for primary hyperoxaluria type 1.

  • Oct 6, 2025

    Partnered with Chiesi Group to develop gene editing programs for rare diseases.

Arbor Biotechnologies Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Arbor Biotechnologies Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Arbor Biotechnologies's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range103
Year Founded2016
Last FundingMar 18, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.